Involvement of the kynurenine pathway in human glioma pathophysiology

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Adams, Seray ^a   Teo, Charles ^b   McDonald, Kerrie L ^c   Zinger, Anna ^d   Bustamante, Sonia ^c   Lim, Chai K ^a   Sundaram, Gayathri ^f   Braidy, Nady ^e   Brew, Bruce J ^f,g   Guillemin, Gilles J ^a,c,f  

^a MACQUARIE UNIVERSITY   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f St Vincent's Centre for Applied Medical Research   (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 CARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE; CARBOXYLYASE; COMPLEMENTARY DNA; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; KYNURENINASE; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; KYNURENINE AMINOTRANSFERASE; MESSENGER RNA; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG; AMINOCARBOXYMUCONATE-SEMIALDEHYDE DECARBOXYLASE; CD11B ANTIGEN; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; DISACCHARIDE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCURONIC ACID; KYNURENIC ACID; LEUKOCYTE ANTIGEN; O-(GLUCURONIC ACID 2-SULFATE)-(1--4)-O-(2,5)-ANHYDROMANNITOL 6-SULFATE; PICOLINIC ACID; PICOLINIC ACID DERIVATIVE; QUINOLINIC ACID; TRYPTOPHAN;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTE; BRAIN TISSUE; CANCER CELL CULTURE; CANCER TISSUE; CATABOLISM; CHILD; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; FEMALE; FETUS; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; KYNURENINE PATHWAY; MALE; MASS FRAGMENTOGRAPHY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SCHOOL CHILD; BIOSYNTHESIS; BLOOD; BRAIN TUMOR; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; TUMOR CELL CULTURE;

ANTIGENS, CD; ANTIGENS, CD11B; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ASTROCYTES; BIOSYNTHETIC PATHWAYS; BRAIN NEOPLASMS; CARBOXY-LYASES; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISACCHARIDES; GENE EXPRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOMA; GLUCURONATES; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; KYNURENIC ACID; KYNURENINE; PICOLINIC ACIDS; QUINOLINIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRYPTOPHAN; TRYPTOPHAN OXYGENASE; TUMOR CELLS, CULTURED;

EID: 84913534316     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112945     Document Type: Article

References (61)

1. Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, et al. Identification of Potential Serum Biomarkers of Glioblastoma: Serum Osteopontin Levels Correlate with Poor Prognosis. Cancer Epidemiology Biomarkers & Prevention. 2010;19:1409-1422.
2. DeAngelis LM. Medical progress: Brain tumors. New England Journal of Medicine. 2001;344:114-123.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine. 2005;352:987-996.
4. McLendon RE, Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer. 2003;98:1745-1748.
5. Phillips RS. Structure, mechanism, and substrate specificity of kynureninase. Biochimica Et Biophysica Acta-Proteins and Proteomics. 2011;1814:1481-1488.
6. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. Febs Journal. 2012;279:1356-1365.
7. Stone TW, Addae JI. The pharmacological manipulation of glutamate receptors and neuroprotection. European Journal of Pharmacology. 2002;447:285-296.
8. Pereira EF, Hilmas C, Santos MD, Alkondon M, Maelicke A, et al. Unconventional ligands and modulators of nicotinic receptors. J Neurobiol. 2002;53:479-500.
9. Ohshiro H, Tonai-Kachi H, Ichikawa K. GPR35 is a functional receptor in rat dorsal root ganglion neurons. Biochemical and Biophysical Research Communications. 2008;365:344-348.
10. Lugo-Huitron R, Blanco-Ayala T, Ugalde-Muniz P, Carrillo-Mora P, Pedraza-Chaverri J, et al. On the antioxidant properties of kynurenic acid: Free radical scavenging activity and inhibition of oxidative stress. Neurotoxicology and Teratology. 2011;33:538-547.
11. Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astelbauer F, et al. Characterization of an indoleamine 2, 3-dioxygenase-like protein found in humans and mice. Gene. 2007;396:203-213.
12. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, et al. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Cancer Res. 1990;50:2863-2867.
13. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. Journal of Experimental Medicine. 1999;189:1363-1372.
14. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2, 3-dioxygenase. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:2497-2502.
15. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med. 2003;9:1269-1274.
16. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006;12:1144-1151.
17. Karanikas V, Zamanakou M, Kerenid T, Dahabreh J, Hevas A, et al. Indoleamine 2, 3-dioxygenose (IDO) expression in lung cancer. Cancer Biology & Therapy. 2007;6:1258-1262.
18. Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, et al. Indoleamine 2, 3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clinical Cancer Research. 2005;11:6030-6039.
19. Urakawa H, Nishida Y, Nakashima H, Shimoyama Y, Nakamura S, et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in high grade osteosarcoma. Clinical & Experimental Metastasis. 2009;26:1005-1012.
20. Miyazaki T, Moritake K, Yamada K, Hara N, Osago H, et al. Indoleamine 2, 3-dioxygenase as a new target for malignant glioma therapy Laboratory investigation. Journal of Neurosurgery. 2009;111:230-237.
21. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, et al. Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim Biophys Acta. 1989;1012:140-147.
22. Schmidt SK, Muller A, Heseler K, Woite C, Spekker K, et al. Antimicrobial and immunoregulatory properties of human tryptophan 2, 3-dioxygenase. European Journal of Immunology. 2009;39:2755- 2764.
23. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478:197-203.
24. Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, et al. IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival. Clinical Cancer Research. 2012;18:6110-6121.
25. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, et al. Tryptophan Catabolism by Indoleamine 2, 3- Dioxygenase 1 Alters the Balance of T(H)17 to Regulatory T Cells in HIV Disease. Science Translational Medicine. 2010;2:12.
26. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176:6752-6761.
27. Gibbons HA, Hughes SA, Van Roon-Mom W, Greenwood JA, Narayan PJ, et al. Cellular composition of human glial cultures from adult biopsy brain tissue. Journal of Neuroscience Methods. 2007;166:89-98.
28. Juhasz C, Chugani DC, Muzik O, Wu DF, Sloan AE, et al. In vivo uptake and metabolism of alpha-[C- 11] methyl-L-tryptophan in human brain tumors. Journal of Cerebral Blood Flow and Metabolism. 2006;26:345-357.
29. Grant RS, Naif H, Espinosa M, Kapoor V. IDO induction in IFN-gamma activated astroglia: A role in improving cell viability during oxidative stress. Redox Rep. 2000;5:101-104.
30. Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, et al. Characterization of the Kynurenine Pathway in Human Neurons. J Neurosci. 2007;27:12884-12892.
31. Suzuki Y, Suda T, Asada K, Miwa S, Suzuki M, et al. Serum Indoleamine 2, 3-Dioxygenase Activity Predicts Prognosis of Pulmonary Tuberculosis. Clinical and Vaccine Immunology. 2012;19:436-442.
32. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: Effect on tumor-infiltrating T cells. Clinical Cancer Research. 2006;12:1144-1151.
33. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189:1363-1372.
34. Forouzandeh F, Jalili RB, Germain M, Duronio V, Ghahary A. Differential immunosuppressive effect of indoleamine 2, 3-dioxygenase (IDO) on primary human CD4(+) and CD8 (+) T cells. Mol Cell Biochem. 2008;309:1-7.
35. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, et al. Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2, 3- Dioxygenase. J Exp Med. 2002;196:459-468.
36. Yu P, Li Z, Zhang L, Tagle DA, Cai T. Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family. Gene. 2006;365:111-118.
37. Guidetti P, Amori L, Sapko MT, Okuno E, Schwarcz R. Mitochondrial aspartate aminotransferase: A third kynurenate-producing enzyme in the mammalian brain. J Neurochem. 2007;102:103-111.
38. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, et al. Kynurenine pathway metabolism in human astrocytes: A paradox for neuronal protection. Journal of Neurochemistry. 2001;78:842-853.
39. Wejksza K, Rzeski W, Okuno E, Kandefer-Szerszen M, Albrecht J, et al. Demonstration of Kynurenine Aminotransferases I and II and Characterization of Kynurenic Acid Synthesis in Oligodendrocyte Cell Line (OLN-93). Neurochem Res. 2005;30:963-968.
40. Guidetti P, Okuno E, Schwarcz R. Characterization of rat brain kynurenine aminotransferases I and II. J Neurosci Res. 1997;50:457-465.
41. Van Gool AR, Verkerk R, Fekkes D, Bannink M, Sleijfer S, et al. Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: Course and relationship with psychiatric status. Psychiatry and Clinical Neurosciences. 2008;62:597-602.
42. Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, et al. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behavior and Immunity. 2011;25:1576-1581.
43. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, et al. Kynurenine pathway in major depression: Evidence of impaired neuroprotection. Journal of Affective Disorders. 2007;98:143-151.
44. Long CL, Hill HN, Weinstock IM, Henderson LM. STUDIES OF THE ENZYMATIC TRANSFORMATION OF 3-HYDROXYANTHRANILATE TO QUINOLINATE. Journal of Biological Chemistry. 1954;211:405-417.
45. Coggan SE, Smythe GA, Bilgin A, Grant RS. Age and circadian influences on picolinic acid concentrations in human cerebrospinal fluid. Journal of Neurochemistry. 2009;108:1220-1225.
46. Martynowski D, Eyobo Y, Li T, Yang K, Liu A, et al. Crystal structure of alpha-amino-betacarboxymuconate- epsilon-semialdehyde decarboxylase: insight into the active site and catalytic mechanism of a novel decarboxylation reaction. Biochemistry. 2006;45:10412-10421.
47. Ikeda M, Tsuji H, Nakamura S, Ichiyama A, Nishizuk. Y. et al. Studies on biosynthesis of nicotinamide adenine dinucleotide.2. a role of picolinic carboxylase in biosynthesis of nicotinamide adenine dinucleotide from tryptophan in mammals. Journal of Biological Chemistry. 1965;240:1395.
48. Pucci L, Perozzi S, Cimadamore F, Orsomando G, Raffaelli N. Tissue expression and biochemical characterization of human 2-amino 3-carboxymuconate 6-semialdehyde decarboxylase, a key enzyme in tryptophan catabolism. Febs J. 2007;274:827-840.
49. Ying W. NAD+ and NADH in brain functions, brain diseases and brain aging. Front Biosci. 2007;12:1863-1888.
50. Braidy N, Guillemin GJ, Mansour H, Chan-Ling T, Grant R. Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats. Febs Journal. 2011;278:4425-4434.
51. Adams S, Braidy N, Bessede A, Brew BJ, Grant R, et al. The Kynurenine Pathway in Brain Tumor Pathogenesis (vol 72, pg 5649, 2012).
52. Adams S, Braidy N, Bessede A, Brew BJ, Grant R, et al. Cancer Research. 2012;72:6524-6524.
53. Sahm F, Oezen I, Opitz CA, Radlwimmer B, von Deimling A, et al. The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. Cancer Res. 2013;73:3225-3234.
54. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13:465-477.
55. Locasale JW, Melman T, Song SS, Yang XM, Swanson KD, et al. Metabolomics of Human Cerebrospinal Fluid Identifies Signatures of Malignant Glioma. Molecular & Cellular Proteomics. 2012.11.
56. Jung CS, Unterberg AW, Hartmann C. Diagnostic markers for glioblastoma. Histology and Histopathology. 2011;26:1327-1341.
57. Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, et al. The indoleamine-2, 3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. Plos One. 2011;6:e19823.
58. Gomez GG, Kruse CA. Isolation and Culture of Human Brain Tumor Cells. 2003; Cancer Cell Culture: Methods and Protocols.
59. Smythe GA, Poljak A, Bustamante S, Braga O, Maxwell A, et al. ECNI GC-MS analysis of picolinic and quinolinic acids and their amides in human plasma, CSF, and brain tissue. In:, Allegri G, Costa CVL, Ragazzi E, Steinhart H, Varesio L, editors., Developments in Tryptophan and Serotonin Metabolism.New York: Kluwer Academic/Plenum Publ. 2003. pp. 705-712.
60. Kapoor V, Kapoor R, Chalmers J. Kynurenic acid, an endogenous glutamate antagonist, in SHR and WKY rats: possible role in central blood pressure regulation. Clin Exp Pharmacol Physiol. 1994;21:891- 896.
61. Adams S, Braidy N, Bessede A, Brew BJ, Grant R, et al. The kynurenine pathway in brain tumor pathogenesis. Cancer Res. 2012;72:5649-5657.